GLP-1 Drugs Don't Cause Dangerous Blood Sugar Drops in Developing Rat Pups

Researchers performed oral glucose tolerance tests (OGTT) and intraperitoneal glucose tolerance tests (IPGTT) in 2-week-old Wistar rat pups, comparing serum glucose, insulin, and incretin hormone levels between the two routes. They then administered standard therapeutic doses of linagliptin (DPP-4 inhibitor) and liraglutide (GLP-1 agonist) to developing pups and monitored for hypoglycemia.

Extremely premature babies frequently develop dangerously high blood sugar, but treating them with insulin is risky because it can cause hypoglycemia — which can damage the developing brain. If incretin-based drugs (GLP-1 agonists or DPP-4 inhibitors) can lower blood sugar without causing hypoglycemia in developing organisms, they could offer a much safer treatment option for this vulnerable population.

Neonatal hyperglycemia management is a significant unmet need in neonatal intensive care. GLP-1-based therapies are already transforming adult diabetes and obesity treatment. If their safety profile extends to the developing neonatal system, it could open an entirely new clinical application for these peptide drugs — protecting the most vulnerable patients from both hyperglycemia and the risks of insulin treatment.

This is an animal study in rats — results may not directly translate to human preterm infants, whose metabolic systems differ from rodents. The 2-week-old rat pup is an imperfect model for human prematurity. No hyperglycemic model was tested — the drugs were given to normal pups, not to pups with the kind of hyperglycemia seen in preterm infants. Clinical trials in neonates would be needed before any treatment recommendation.